Choose Your Language
Home  /  News


NIFTY was the first CFDA Approved Non-Invasive Prenatal Genetic Test

--- 1 Sep 2020

Did you know BGI Diagnostics’ NIFTY™ test was the first NIPT based on Next Generation Sequencing Technology to be Approved by the China Food and Drug Administration (CFDA)? On June 30, 2014, the CFDA approved the registration of BGI’s BGISEQ-1000 and BGISEQ-100 sequencers, and its prenatal genetic testing kits for NIFTY™ (Non-Invasive Fetal Trisomy test). This is the first genetic…

BGI Study Confirms Accuracy Of Its Non-Invasive Prenatal Test, NIFTY®, In Nearly 147,000 Pregnancies

--- 28 Jun 2020

BGI has published a study tracking the clinical performance of its whole genome sequencing-based non-invasive prenatal test (the NIFTY® test) in nearly 147,000 pregnancies, the largest such study to date. The results showed high sensitivity and specificity and no significant difference between high-risk and low-risk pregnant women. The study, published today in the journal Ultrasound Obstetrics and Gynecology, reported on…